Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,834 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pilot study of gemcitabine (10 mg/m(2) per min) and cisplatin.
Poplin E, Benson A 3rd, Musanti R, Rubin E, Mulcahy M. Poplin E, et al. Among authors: rubin e. Cancer Chemother Pharmacol. 2002 Jul;50(1):80-3. doi: 10.1007/s00280-002-0461-3. Epub 2002 May 9. Cancer Chemother Pharmacol. 2002. PMID: 12111116 Clinical Trial.
A phase I trial of weekly paclitaxel, 13- cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies.
Thalasila A, Poplin E, Shih J, Dvorzhinski D, Capanna T, Doyle-Lindrud S, Beers S, Goodin S, Rubin E, DiPaola RS. Thalasila A, et al. Among authors: rubin e. Cancer Chemother Pharmacol. 2003 Aug;52(2):119-24. doi: 10.1007/s00280-003-0644-6. Epub 2003 May 24. Cancer Chemother Pharmacol. 2003. PMID: 12768320 Clinical Trial.
Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach.
Mehnert JM, Tan AR, Moss R, Poplin E, Stein MN, Sovak M, Levinson K, Lin H, Kane M, Gounder M, Lin Y, Shih WJ, White E, Rubin EH, Karantza V. Mehnert JM, et al. Among authors: rubin eh. Mol Cancer Ther. 2011 Aug;10(8):1509-19. doi: 10.1158/1535-7163.MCT-10-0944. Epub 2011 Jun 16. Mol Cancer Ther. 2011. PMID: 21680752 Free PMC article. Clinical Trial.
A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies.
Rubin EH, de Alwis DP, Pouliquen I, Green L, Marder P, Lin Y, Musanti R, Grospe SL, Smith SL, Toppmeyer DL, Much J, Kane M, Chaudhary A, Jordan C, Burgess M, Slapak CA. Rubin EH, et al. Clin Cancer Res. 2002 Dec;8(12):3710-7. Clin Cancer Res. 2002. PMID: 12473580 Clinical Trial.
1,834 results